Aged
Aged, 80 and over
Androgen Receptor Antagonists
/ pharmacology
Androstenes
/ pharmacology
Antineoplastic Agents
/ pharmacology
Benzamides
Biomarkers, Tumor
/ blood
Circulating Tumor DNA
/ blood
Disease-Free Survival
Drug Resistance, Neoplasm
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Liquid Biopsy
/ methods
Male
Neoplastic Cells, Circulating
/ pathology
Nitriles
Phenylthiohydantoin
/ analogs & derivatives
Predictive Value of Tests
Prognosis
Progression-Free Survival
Prostatic Neoplasms, Castration-Resistant
/ blood
RNA-Seq
Receptors, Androgen
/ blood
Tumor Suppressor Protein p53
/ blood
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 03 2019
15 03 2019
Historique:
received:
18
06
2018
revised:
14
08
2018
accepted:
11
09
2018
pubmed:
14
9
2018
medline:
28
5
2020
entrez:
14
9
2018
Statut:
ppublish
Résumé
To infer the prognostic value of simultaneous androgen receptor ( Overall, no single In an all-comer cohort, tumor burden estimates and
Identifiants
pubmed: 30209161
pii: 1078-0432.CCR-18-1943
doi: 10.1158/1078-0432.CCR-18-1943
pmc: PMC6330086
mid: EMS79626
doi:
Substances chimiques
AR protein, human
0
Androgen Receptor Antagonists
0
Androstenes
0
Antineoplastic Agents
0
Benzamides
0
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Nitriles
0
Receptors, Androgen
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Phenylthiohydantoin
2010-15-3
enzalutamide
93T0T9GKNU
abiraterone
G819A456D0
Types de publication
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1766-1773Subventions
Organisme : Cancer Research UK
ID : C19198/A1533
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2018 American Association for Cancer Research.
Références
Cancer Discov. 2017 Jul;7(7):736-749
pubmed: 28411207
J Clin Oncol. 2018 Apr 1;36(10):991-999
pubmed: 29261439
Eur Urol. 2018 May;73(5):687-693
pubmed: 29429804
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
Cancer Discov. 2018 Apr;8(4):444-457
pubmed: 29367197
Eur Urol. 2017 Jan;71(1):1-3
pubmed: 27471164
Lancet Oncol. 2009 Mar;10(3):233-9
pubmed: 19213602
Nat Commun. 2016 Nov 29;7:13668
pubmed: 27897170
Eur Urol. 2018 Feb;73(2):178-211
pubmed: 28655541
Eur Urol. 2015 Apr;67(4):795-802
pubmed: 25454616
Eur Urol. 2017 Dec;72(6):e168-e169
pubmed: 28688614
Cancer Cell. 2017 Oct 9;32(4):474-489.e6
pubmed: 29017058
Lancet Oncol. 2015 Oct;16(13):1324-34
pubmed: 26342236
J Clin Oncol. 2014 Mar 1;32(7):671-7
pubmed: 24449231
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
JAMA Oncol. 2016 Nov 1;2(11):1441-1449
pubmed: 27262168
Prostate Cancer Prostatic Dis. 2018 Jun;21(2):260-268
pubmed: 29302046
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
Cancer Discov. 2013 Sep;3(9):1020-9
pubmed: 23779130
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Eur Urol. 2017 Aug;72(2):192-200
pubmed: 28104311
Ann Oncol. 2017 Jul 1;28(7):1508-1516
pubmed: 28472366
J Clin Oncol. 2008 Mar 1;26(7):1148-59
pubmed: 18309951
Urol Oncol. 2017 Aug;35(8):535
pubmed: 28623072
Elife. 2013 Jun 25;2:e00747
pubmed: 23805382
Sci Transl Med. 2015 Nov 4;7(312):312re10
pubmed: 26537258
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Oncogene. 2012 Nov 8;31(45):4759-67
pubmed: 22266865
J Clin Oncol. 2017 Jul 1;35(19):2149-2156
pubmed: 28384066